Machine Learning Classification of Time since BNT162b2 COVID-19 Vaccination Based on Array-Measured Antibody Activity
暂无分享,去创建一个
Fei Huang | Kai-Yan Feng | Yunpeng Cai | W. Guo | Qinglan Ma | Tao Huang | Wei Guo
[1] Tao Huang,et al. Identification of Genes Associated with the Impairment of Olfactory and Gustatory Functions in COVID-19 via Machine-Learning Methods , 2023, Life.
[2] Lei Chen,et al. PMPTCE-HNEA: Predicting metabolic pathway types of chemicals and enzymes with a heterogeneous network embedding algorithm , 2023, Current Bioinformatics.
[3] J. Eiros,et al. Evolution of antibody profiles against SARS-CoV-2 in experienced and naïve vaccinated elderly people , 2023, Frontiers in Immunology.
[4] Fei Huang,et al. Identification of Smoking-Associated Transcriptome Aberration in Blood with Machine Learning Methods , 2023, BioMed research international.
[5] Fei Huang,et al. Analysis and prediction of protein stability based on interaction network, gene ontology, and KEGG pathway enrichment scores. , 2023, Biochimica et biophysica acta. Proteins and proteomics.
[6] Lei Chen,et al. A model with deep analysis on a large drug network for drug classification. , 2023, Mathematical biosciences and engineering : MBE.
[7] Tao Huang,et al. Identification of Methylation Signatures and Rules for Sarcoma Subtypes by Machine Learning Methods , 2022, BioMed research international.
[8] P. Horváth,et al. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population , 2022, Frontiers in Immunology.
[9] A. Varizhuk,et al. Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern , 2022, International journal of molecular sciences.
[10] Minal K. Patel,et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant , 2022, The Lancet Infectious Diseases.
[11] Lei Chen,et al. Identification of human protein subcellular location with multiple networks , 2022, Current Protoemics.
[12] A. Sette,et al. Humoral and cellular immune memory to four COVID-19 vaccines , 2022, Cell.
[13] Lei Chen,et al. Drug-Drug Interactions Prediction Using Fingerprint Only , 2022, Computational and mathematical methods in medicine.
[14] S. Ünal,et al. Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population , 2022, Age and ageing.
[15] E. Dolgin. Pan-coronavirus vaccine pipeline takes form , 2022, Nature Reviews Drug Discovery.
[16] A. Linē,et al. Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients , 2022, Journal of Translational Medicine.
[17] P. Horváth,et al. Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray , 2022, Frontiers in Immunology.
[18] Tao Huang,et al. Identification of Cell Markers and Their Expression Patterns in Skin Based on Single-Cell RNA-Sequencing Profiles , 2022, Life.
[19] Lei Chen,et al. iATC-NFMLP: Identifying classes of anatomical therapeutic chemicals based on drug networks, fingerprints and multilayer perceptron , 2022, Current Bioinformatics.
[20] D. Altmann,et al. COVID-19 vaccination: The road ahead , 2022, Science.
[21] J. Knight,et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study , 2022, The Lancet Microbe.
[22] A. Mechaly,et al. A Novel Quantitative Multi-Component Serological Assay for SARS-CoV-2 Vaccine Evaluation , 2022, Analytical chemistry.
[23] Xinxin Zhang,et al. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic , 2022, Frontiers of Medicine.
[24] S. Whelan,et al. Germinal centre-driven maturation of B cell response to mRNA vaccination , 2022, Nature.
[25] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[26] J. Suh,et al. Comparing SARS-CoV-2 Antibody Responses after Various COVID-19 Vaccinations in Healthcare Workers , 2022, Vaccines.
[27] K. Zheng,et al. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 , 2022, Frontiers in Immunology.
[28] C. Zheng,et al. Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines , 2022, Journal of medical virology.
[29] A. Linē,et al. Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients , 2022, Journal of translational medicine.
[30] Vikram Thakur,et al. OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fear , 2021, Journal of medical virology.
[31] D. Easton,et al. Covid-19 Vaccine Effectiveness in New York State , 2021, The New England journal of medicine.
[32] H. Scheiblauer,et al. Antibody response to SARS-CoV-2 for more than one year − kinetics and persistence of detection are predominantly determined by avidity progression and test design , 2021, Journal of Clinical Virology.
[33] J. Koeleman,et al. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study , 2021, Journal of Infection.
[34] Yicheng Guo,et al. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses , 2021, Emerging microbes & infections.
[35] S. Schubl,et al. Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination , 2021, NPJ vaccines.
[36] S. Bernardini,et al. Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution , 2021, International Immunopharmacology.
[37] H. Legido-Quigley,et al. How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic , 2021, The Lancet.
[38] Y. Kreiss,et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.
[39] I. Suriapranata,et al. Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia , 2021, International Journal of Infectious Diseases.
[40] M. Takeda. Proteolytic activation of SARS‐CoV‐2 spike protein , 2021, Microbiology and immunology.
[41] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.
[42] Anna E. Merrill,et al. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors , 2021, Transfusion and Apheresis Science.
[43] G. Shurin,et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects , 2021, Microbiology spectrum.
[44] T. Fiolet,et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.
[45] S. Safiri,et al. Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies , 2021, Reviews in medical virology.
[46] Tao Zeng,et al. Identification of Microbiota Biomarkers With Orthologous Gene Annotation for Type 2 Diabetes , 2021, Frontiers in Microbiology.
[47] Tao Li,et al. Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2 , 2021, Journal of Advanced Research.
[48] Yu-Dong Cai,et al. Identifying Protein Subcellular Locations With Embeddings-Based node2loc , 2021, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[49] A. Mantovani,et al. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in recovered individuals with symptomatic COVID-19. , 2021, The Journal of clinical investigation.
[50] J. Rossowska,et al. Immune Response to COVID-19 mRNA Vaccine—A Pilot Study , 2021, Vaccines.
[51] B. Chain,et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose , 2021, Science.
[52] Qiu Sun,et al. Antibodies and Vaccines Target RBD of SARS-CoV-2 , 2021, Frontiers in Molecular Biosciences.
[53] Ahmed Abdul Azim,et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. , 2021, JAMA.
[54] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.
[55] D. Klonoff,et al. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. , 2021, European review for medical and pharmacological sciences.
[56] H. Leier,et al. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2 , 2021, Cell Reports.
[57] M. Battegay,et al. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray , 2021, Nature communications.
[58] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[59] J. Mascola,et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.
[60] Tao Zeng,et al. Distinguishing Glioblastoma Subtypes by Methylation Signatures , 2020, Frontiers in Genetics.
[61] V. Thiel,et al. Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.
[62] Min Zheng,et al. A systematic review of SARS-CoV-2 vaccine candidates , 2020, Signal Transduction and Targeted Therapy.
[63] S. Bartell,et al. Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California , 2020, Scientific Reports.
[64] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.
[65] A. Parasher. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment , 2020, Postgraduate Medical Journal.
[66] M. Busch,et al. Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray , 2020, Scientific Reports.
[67] S. Kang,et al. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses , 2020, Infection, Genetics and Evolution.
[68] A. Munasinghe,et al. SARS-CoV-2 and the pandemic of COVID-19 , 2020, Postgraduate Medical Journal.
[69] J. Dye,et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.
[70] Vineet D. Menachery,et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.
[71] K. Dev,et al. Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development , 2020, Transboundary and emerging diseases.
[72] J. Peiris,et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections , 2020, Cell Reports.
[73] M. Battegay,et al. Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray , 2020, Nature Communications.
[74] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[75] M. Letko,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[76] W. Liu,et al. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.
[77] Xiangbo Chen,et al. Evaluation of Plasma Extracellular Vesicle MicroRNA Signatures for Lung Adenocarcinoma and Granuloma With Monte-Carlo Feature Selection Method , 2019, Front. Genet..
[78] Lei Chen,et al. Identification of gene expression signatures across different types of neural stem cells with the Monte‐Carlo feature selection method , 2018, Journal of cellular biochemistry.
[79] Tie-Yan Liu,et al. LightGBM: A Highly Efficient Gradient Boosting Decision Tree , 2017, NIPS.
[80] Moon-Hyang Park,et al. Clear Cell Carcinomas of the Ovary: A Multi-Institutional Study of 129 Cases in Korea With Prognostic Significance of Emi1 and Galectin-3 , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[81] R. Tibshirani,et al. Regression shrinkage and selection via the lasso: a retrospective , 2011 .
[82] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[83] Jan Gorodkin,et al. Comparing two K-category assignments by a K-category correlation coefficient , 2004, Comput. Biol. Chem..
[84] Fuhui Long,et al. Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy , 2003, IEEE Transactions on Pattern Analysis and Machine Intelligence.
[85] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[86] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[87] Huan Liu,et al. Incremental Feature Selection , 1998, Applied Intelligence.
[88] L. Breiman. Better subset regression using the nonnegative garrote , 1995 .
[89] Ron Kohavi,et al. A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.
[90] David A. Landgrebe,et al. A survey of decision tree classifier methodology , 1991, IEEE Trans. Syst. Man Cybern..
[91] OUP accepted manuscript , 2022, Age And Ageing.
[92] Jan Komorowski,et al. BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm486 Data and text mining Monte Carlo , 2022 .
[93] Vladimir Vapnik,et al. Support-vector networks , 2004, Machine Learning.
[94] Nitesh V. Chawla,et al. SMOTE: Synthetic Minority Over-sampling Technique , 2002, J. Artif. Intell. Res..
[95] Peter E. Hart,et al. Nearest neighbor pattern classification , 1967, IEEE Trans. Inf. Theory.